An Open-label Phase 3 Trial to Evaluate the Safety and Tolerability of Egalet ADER Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Noncancer Pain
Phase of Trial: Phase III
Latest Information Update: 16 May 2019
Price : $35 *
At a glance
- Drugs Oxycodone (Primary)
- Indications Pain
- Focus Adverse reactions; Registrational
- Sponsors Zyla Life Sciences
- 16 Nov 2017 Top-line results presented in an Egalet media release.
- 01 Aug 2017 Status changed from active, no longer recruiting to completed.
- 22 Nov 2016 Status changed from recruiting to active, no longer recruiting.